Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Mineralys Therapeutics Inc.

Headquarters: Philadelphia, PA, United States of America
Year Founded: 2020
Status: Public
Industry Sector: HealthTechnology
CEO: Jon Congleton
Number Of Employees: 51
Enterprise Value: $399,337,876
PE Ratio: -3.71
Exchange/Ticker 1: NASDAQ:MLYS
Exchange/Ticker 2: N/A
Latest Market Cap: $672,780,608
BioCentury | Mar 14, 2025
Finance

Insilico, Lila draw nine-figure venture rounds: Finance Report

Plus: public companies Beam, Tarsus and Mineralys raise follow-ons
BioCentury | Mar 12, 2025
Product Development

Oral peptide win for Protagonist/J&J, Beam’s base editor POC, and more: Clinical Report

Protagonist data led to week’s biggest share price gain, while Arvinas saw biggest loss: in BioCentury’s latest Clinical Report
BioCentury | Feb 10, 2024
Finance

Public equity report: IPOs for Kyverna, Metagenomi; 4D, Sana among follow-ons

Plus PIPEs for Adverum, Autolus, Mineralys, Silence, PepGen, Sensorion, Tenaya, Jasper and others
BioCentury | Jan 6, 2024
Management Tracks

Management moves abound on eve of JPM, including new chairs for Sobi, Corteria

Plus: Zaderej to retire as AxoGen CEO and updates from AxoGen, Delfi, Illumina, Evozyne, Kiyatec, Sosei, Twist, Novocure, Be Bio, Novo Holdings, Bioluminescence and more
BioCentury | Sep 18, 2023
Product Development

Data comp: four hypertension candidates advancing in the clinic

Idorsia’s aprocitentan under review, while Mineralys and AZ prepare for Phase III trials and Alnylam runs two more Phase II studies
BioCentury | Sep 7, 2023
Deals

Idorsia’s hypertension lifeline

Swiss biotech Idorsia hopes near-term commercial opportunity for aprocitentan will spur investors to refinance the company
BioCentury | Aug 4, 2023
Finance

Biotechs that could enter the IPO queue as crossovers await liquidity

Among dozens of companies that raised crossover cash before markets turned sour, some may soon have what it takes to go public
BioCentury | Jun 23, 2023
Finance

How Apogee will test the IPO market’s appetite for preclinical risk

Backed by Fairmount Funds and Venrock and spun out of Paragon, the young start-up has an experienced CFO and is aiming for familiar targets
BioCentury | Jun 13, 2023
Finance

Turnstone to test public markets’ appetite for a biotech still waiting for clinical data

Now focused on TILs with data due in mid-2024, the company would be the fourth biotech to raise at least $20M in a NASDAQ listing this year
BioCentury | May 16, 2023
Finance

Bright spots amid the bear, IPO success story & Bio€quity ‘24 preview 

Takeaways from Bio€quity Europe on the latest BioCentury This Week
Items per page:
1 - 10 of 19